Cargando…

Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway

Nonsteroidal anti-inflammatory drugs (NSAIDs), including salicylic acid (SA), target mammalian cyclooxygenases. In plants, SA is a defense hormone that regulates NON-EXPRESSOR OF PATHOGENESIS RELATED GENES 1 (NPR1), the master transcriptional regulator of immunity-related genes. We identify that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishihama, Nobuaki, Choi, Seung-won, Noutoshi, Yoshiteru, Saska, Ivana, Asai, Shuta, Takizawa, Kaori, He, Sheng Yang, Osada, Hiroyuki, Shirasu, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674334/
https://www.ncbi.nlm.nih.gov/pubmed/34911942
http://dx.doi.org/10.1038/s41467-021-27489-w
_version_ 1784615629141049344
author Ishihama, Nobuaki
Choi, Seung-won
Noutoshi, Yoshiteru
Saska, Ivana
Asai, Shuta
Takizawa, Kaori
He, Sheng Yang
Osada, Hiroyuki
Shirasu, Ken
author_facet Ishihama, Nobuaki
Choi, Seung-won
Noutoshi, Yoshiteru
Saska, Ivana
Asai, Shuta
Takizawa, Kaori
He, Sheng Yang
Osada, Hiroyuki
Shirasu, Ken
author_sort Ishihama, Nobuaki
collection PubMed
description Nonsteroidal anti-inflammatory drugs (NSAIDs), including salicylic acid (SA), target mammalian cyclooxygenases. In plants, SA is a defense hormone that regulates NON-EXPRESSOR OF PATHOGENESIS RELATED GENES 1 (NPR1), the master transcriptional regulator of immunity-related genes. We identify that the oxicam-type NSAIDs tenoxicam (TNX), meloxicam, and piroxicam, but not other types of NSAIDs, exhibit an inhibitory effect on immunity to bacteria and SA-dependent plant immune response. TNX treatment decreases NPR1 levels, independently from the proposed SA receptors NPR3 and NPR4. Instead, TNX induces oxidation of cytosolic redox status, which is also affected by SA and regulates NPR1 homeostasis. A cysteine labeling assay reveals that cysteine residues in NPR1 can be oxidized in vitro, leading to disulfide-bridged oligomerization of NPR1, but not in vivo regardless of SA or TNX treatment. Therefore, this study indicates that oxicam inhibits NPR1-mediated SA signaling without affecting the redox status of NPR1.
format Online
Article
Text
id pubmed-8674334
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86743342022-01-04 Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway Ishihama, Nobuaki Choi, Seung-won Noutoshi, Yoshiteru Saska, Ivana Asai, Shuta Takizawa, Kaori He, Sheng Yang Osada, Hiroyuki Shirasu, Ken Nat Commun Article Nonsteroidal anti-inflammatory drugs (NSAIDs), including salicylic acid (SA), target mammalian cyclooxygenases. In plants, SA is a defense hormone that regulates NON-EXPRESSOR OF PATHOGENESIS RELATED GENES 1 (NPR1), the master transcriptional regulator of immunity-related genes. We identify that the oxicam-type NSAIDs tenoxicam (TNX), meloxicam, and piroxicam, but not other types of NSAIDs, exhibit an inhibitory effect on immunity to bacteria and SA-dependent plant immune response. TNX treatment decreases NPR1 levels, independently from the proposed SA receptors NPR3 and NPR4. Instead, TNX induces oxidation of cytosolic redox status, which is also affected by SA and regulates NPR1 homeostasis. A cysteine labeling assay reveals that cysteine residues in NPR1 can be oxidized in vitro, leading to disulfide-bridged oligomerization of NPR1, but not in vivo regardless of SA or TNX treatment. Therefore, this study indicates that oxicam inhibits NPR1-mediated SA signaling without affecting the redox status of NPR1. Nature Publishing Group UK 2021-12-15 /pmc/articles/PMC8674334/ /pubmed/34911942 http://dx.doi.org/10.1038/s41467-021-27489-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ishihama, Nobuaki
Choi, Seung-won
Noutoshi, Yoshiteru
Saska, Ivana
Asai, Shuta
Takizawa, Kaori
He, Sheng Yang
Osada, Hiroyuki
Shirasu, Ken
Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title_full Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title_fullStr Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title_full_unstemmed Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title_short Oxicam-type non-steroidal anti-inflammatory drugs inhibit NPR1-mediated salicylic acid pathway
title_sort oxicam-type non-steroidal anti-inflammatory drugs inhibit npr1-mediated salicylic acid pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674334/
https://www.ncbi.nlm.nih.gov/pubmed/34911942
http://dx.doi.org/10.1038/s41467-021-27489-w
work_keys_str_mv AT ishihamanobuaki oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT choiseungwon oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT noutoshiyoshiteru oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT saskaivana oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT asaishuta oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT takizawakaori oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT heshengyang oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT osadahiroyuki oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway
AT shirasuken oxicamtypenonsteroidalantiinflammatorydrugsinhibitnpr1mediatedsalicylicacidpathway